In a 26‑year‑old postpartum woman (6 months postpartum) with a baseline weight of 61 kg who has been taking oral semaglutide (Rybelsus) 14 mg daily for three months and now stops, what weight loss is expected after the three months of therapy and what weight regain is expected six months after discontinuation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Expected Weight Loss and Weight Regain with Oral Semaglutide 14 mg

After 3 months of oral semaglutide 14 mg at a baseline weight of 61 kg, expect approximately 2.4-3.7 kg weight loss (4-6% total body weight loss), bringing weight to approximately 57-59 kg. Six months after stopping, expect to regain approximately 60-70% of the lost weight, resulting in a final weight of approximately 59-60 kg.

Weight Loss During Treatment (3 Months)

Based on FDA-approved data for oral semaglutide (Rybelsus) 14 mg, the expected weight loss at 26 weeks (approximately 6 months) ranges from 3.1-4.4 kg in patients with type 2 diabetes 1. However, your patient stopped at 3 months, which represents approximately half the treatment duration studied.

Calculating 3-Month Weight Loss:

  • Starting weight: 61 kg
  • Expected weight loss at 3 months: Approximately 4-6% of baseline body weight
  • Absolute weight loss: 2.4-3.7 kg
  • Expected weight at 3 months: 57-59 kg

Real-world data supports this estimate, showing that patients achieve approximately 6.45% weight loss at 3 months with semaglutide therapy 2. For a 61 kg patient, this translates to approximately 3.9 kg loss.

Important Context:

The oral formulation at 14 mg daily (approved for diabetes) produces less weight loss than the higher-dose oral formulations (25-50 mg) or subcutaneous semaglutide 2.4 mg weekly used specifically for obesity treatment 3. The OASIS-1 trial showed 17.1% weight loss with oral semaglutide 50 mg over 68 weeks 3, but your patient is on the lower 14 mg dose.

Weight Regain After Discontinuation (6 Months Post-Stopping)

The critical issue is that GLP-1 receptor agonists do not provide lasting weight loss after discontinuation. While the provided evidence doesn't include specific studies on weight regain after oral semaglutide discontinuation, the pharmacology and clinical experience with GLP-1 receptor agonists consistently demonstrate substantial weight regain when treatment stops.

Expected Weight Regain Pattern:

  • Typical regain: 60-70% of lost weight within 6-12 months of discontinuation
  • For this patient: If 3 kg was lost, expect to regain approximately 1.8-2.1 kg over 6 months
  • Final weight at 6 months post-discontinuation: Approximately 59-60 kg

Key Mechanistic Considerations:

Why weight regain occurs:

  • Semaglutide's half-life is approximately 183 hours (7.6 days) for subcutaneous formulation 3
  • Once discontinued, appetite suppression and metabolic effects reverse
  • The underlying biological drive for weight regain remains unchanged
  • No metabolic "reset" occurs with short-term treatment

Postpartum context matters: This 26-year-old woman is 6 months postpartum, a period when weight naturally fluctuates. The 3-month treatment duration is insufficient to establish long-term metabolic changes, making weight regain highly likely without continued pharmacotherapy or intensive lifestyle intervention.

Clinical Pitfalls and Caveats:

  1. Short treatment duration: 3 months is inadequate for sustained weight management. The STEP trials demonstrating robust weight loss used 68+ weeks of treatment 3

  2. Postpartum physiology: Hormonal changes, breastfeeding status, and lifestyle factors in the postpartum period significantly influence weight trajectory independent of medication

  3. Individual variability: Real-world data shows 38% of patients discontinue semaglutide by 12 months 4, and response varies considerably based on diabetes status, baseline weight, and adherence

  4. Dose considerations: The 14 mg oral dose is approved for diabetes, not obesity. Higher doses (25-50 mg oral or 2.4 mg subcutaneous weekly) produce greater weight loss 3

  5. Realistic expectations: At 61 kg baseline, this patient may not have significant obesity (depending on height), and absolute weight loss will be proportionally smaller than in patients with higher baseline weights

The fundamental principle: GLP-1 receptor agonists are chronic disease medications requiring ongoing treatment for sustained benefit. Stopping after 3 months essentially guarantees weight regain, leaving the patient near or at baseline weight within 6-12 months of discontinuation.

References

3
Guideline

american association of clinical endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity/adiposity-based chronic disease - 2025 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2025

Related Questions

In a 59-year-old woman with weight 152 lb, BMI 29, hyperlipidemia, obstructive sleep apnea, and prior cerebrovascular accident, whose weight loss has plateaued on Wegovy (semaglutide) 2.4 mg weekly, can the dose be increased to Wegovy 7.2 mg weekly?
What were the efficacy outcomes and dosing protocol of the 68‑week semaglutide 2.4 mg (subcutaneous) weight‑loss trial in adults with obesity (BMI ≥ 30 kg/m² or ≥ 27 kg/m² with comorbidities)?
What New England Journal of Medicine (NEJM) studies are available on semaglutide (Ozempic)?
Does oral semaglutide (Ribelsus) lose its appetite‑suppressing effectiveness after prolonged use, such as after three years of therapy?
What is the next dose of semaglutide after a patient is on 2.5 mg once weekly?
What are the likely causes and recommended management for persistent hand and oral lesions lasting two months in a 10‑month‑old infant?
Is constipation a symptom of perimenopause in women in their mid‑40s to early 50s?
What is the recommended treatment for a 5‑month‑old infant with TSH 150 mIU/L, free T4 9.6 ng/dL, and free T3 4.1 pg/mL?
In an 83‑year‑old male with Alzheimer’s dementia, hypertension, and hyperlipidemia who is taking memantine and donepezil and has a reversed sleep‑wake cycle causing insomnia, what is the most appropriate pharmacologic treatment?
In a 7‑year‑old on clonidine and lisdexamfetamine (Vyvanse) who exhibits aggression and violent behavior in the late afternoon/evening, how should the medication regimen be optimized and what behavioral strategies should be employed?
Can operating a Coast Guard boat cause or worsen cervical arthritis (cervical spondylosis) or degenerative disc disease in a service member with pre‑existing cervical spine pathology?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.